Bluejay Diagnostics Completes 624 Patient Enrollments in Pivotal Sepsis Trial, Nearing Completion
BJDX sits 15% above its 52-week low of $1.649 on light trading volume (0.2× avg).
Summary
Bluejay Diagnostics announced the completion of 624 patient enrollments in its SYMON-II pivotal clinical trial for its Symphony™ IL-6 sepsis test, nearing the target of 750 patients. This milestone is highly significant for the company, which recently disclosed substantial doubt about its ability to continue as a going concern and a critical need for $20 million in new capital by Q3 2026. Completing enrollment is a major de-risking step in the clinical development process, bringing Bluejay closer to potential FDA 510(k) submission and commercialization of its lead product candidate. Successful trial results and subsequent regulatory approval are crucial for the company's long-term viability and ability to address its financial challenges. Investors will now closely watch for the full completion of enrollment, expected within 2-3 months, and subsequent updates on data analysis and regulatory submission timelines.
At the time of this announcement, BJDX was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $1.65 to $40.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.